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the landscape of tiered regulation 
of breast cancer cell metabolism
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Vitaly A. Selivanov2, Philippe Sabatier4, Marta cascante2,3, Tamar Geiger5* & eytan Ruppin6*
Altered metabolism is a hallmark of cancer, but little is still known about its regulation. In this study, we 
measure transcriptomic, proteomic, phospho-proteomic and fluxomics data in a breast cancer cell-line 
(MCF7) across three different growth conditions. Integrating these multiomics data within a genome 
scale human metabolic model in combination with machine learning, we systematically chart the 
different layers of metabolic regulation in breast cancer cells, predicting which enzymes and pathways 
are regulated at which level. We distinguish between two types of reactions, directly and indirectly 
regulated. Directly-regulated reactions include those whose flux is regulated by transcriptomic 
alterations (~890) or via proteomic or phospho-proteomics alterations (~140) in the enzymes catalyzing 
them. We term the reactions that currently lack evidence for direct regulation as (putative) indirectly 
regulated (~930). Many metabolic pathways are predicted to be regulated at different levels, and those 
may change at different media conditions. Remarkably, we find that the flux of predicted indirectly 
regulated reactions is strongly coupled to the flux of the predicted directly regulated ones, uncovering a 
tiered hierarchical organization of breast cancer cell metabolism. Furthermore, the predicted indirectly 
regulated reactions are predominantly reversible. Taken together, this architecture may facilitate rapid 
and efficient metabolic reprogramming in response to the varying environmental conditions incurred 
by the tumor cells. The approach presented lays a conceptual and computational basis for mapping 
metabolic regulation in additional cancers.
Cancer cells adapt their metabolism to facilitate biomass formation to support their rapid proliferation. 
Transcriptional regulation alone does not account for many of the metabolic alterations observed in cancer1,2, 
suggesting that post-transcriptional, post-translational and protein phosphorylation mechanisms may play 
an important role in modulating cancer metabolism and determining cancer cell phenotypes3–6. Here we aim 
to chart the transcriptional, post-transcriptional and post-translational regulation of MCF7 breast cancer cell 
metabolism on a genome scale. This is performed via measurements of multi-omics data employing MCF7 
breast cancer cells under three different in vitro growth conditions, and its analysis via an integration of this data 
within a genome scale metabolic model (GSMM) of human metabolism. Our approach is inspired by previous 
large-scale omics studies of the multi-level regulation of bacterial metabolism7–9 and yeast10, which have advanced 
our understanding of the organization and regulation of metabolism in these organisms.
Genome scale metabolic modeling is an increasingly widely used computational framework for studying 
metabolism. Given the GSMM of a species alongside contextual information such as growth media and omics 
data, it has been shown that one can fairly reliably predict numerous metabolic phenotypes, including cells’ 
growth rates, metabolite uptake and secretion rates and internal fluxes, gene essentiality, and more. Over the last 
few years, GSMMs have successfully served as a basis for many computational studies of cancer, e.g.11–16. GSMMs 
have also been used to predict post-transcriptional regulation of metabolic enzymes in healthy tissues17 but going 
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beyond that to systematically analyze metabolic regulation in cancer is addressed here for the first time to the best 
of our knowledge.
Results
Data collection and preliminary model-free analysis. We collected omics measurements in MCF7, 
a breast cancer cell line, grown under three different conditions: (1) Minimum Essential Medium (MEM) with 
glucose and without glutamine (MEM-Gln), (2) MEM with glucose and glutamine (MEM) and (3) MEM with 
glucose, glutamine and supplemented with Oligomycin – an inhibitor of ATP synthase that inhibits cell respira-
tion (MEM+Oli). The media were chosen because they reflect multiple stress conditions for the cell: one media 
(glutamine deprivation) is chosen because MCF7 cells rely on glutamine as the main source of energy, and the 
other media (supplement of Oligomycin) is chosen because it emulates tumor hypoxic conditions.
The measurements were repeated twice under each condition at two time points - after 8 and 24 hours, result-
ing in overall 6 × 2 multi-omics datasets. Each such dataset includes the gene-expression of 1372 metabolic genes, 
proteomics for 486 metabolic enzymes (~97% of the measured enzymes have gene expression values), phos-
phorylation values for 71 phosphorylation sites on metabolic enzymes, and flux measurements of 44 metabolic 
reactions (see methods). To obtain flux measurements, we fitted all the data obtained through spectrophotometric 
measurements and 13C assisted metabolomics experiments using our in-house developed software that simulates 
dynamics of metabolites 13C labeling, Isodyn18–22. Fitting the data allows determining the metabolic flux profiles 
of MCF7 breast cancer cells under three different growth conditions (see methods). Figure 1 summarizes the 
qualitative changes in the metabolites and their analysis using Isodyn. The analysis demonstrates a decrease in the 
fluxes of glycolysis, lactate production, pentose phosphate pathway (PPP) activity, tricarboxylic acid cycle (TCA) 
cycle utilization and fatty acid synthesis when the cells are at MEM-Gln growth condition compared to MEM. 
Moreover, increased pyruvate cycle, which is the conversion of pyruvate to oxaloacetate via pyruvate carboxylase 
followed by its conversion to malate and consequently back to pyruvate via malic enzyme, occurs mainly in MCF7 
cells at MEM-Gln condition compared to the MEM growth condition. On the other hand, in the MEM+Oli 
growth condition, increased glycolysis, lactic acid fermentation and pyruvate cycle are observed compared to 
the MEM growth condition, together with decreased TCA cycle activity, PPP and lipogenesis. All measured and 
estimated fluxes and their values are listed in SI Table 1.
To obtain a genome wide view of pathway-level differences in the transcriptional data across the different 
growth conditions, we first compared (using a t-test) the metabolic gene expression values between the different 
growth conditions to identify metabolic pathways that were significantly up or down regulated in any of these 
conditions compared to the others. We found that upon oligomycin treatment, carnitine shuttle pathway is down-
regulated compared to the other growth conditions, as well as the urea cycle/amino group metabolism pathway. 
On the other hand, fatty acid activation and C5-Branched dibasic acid metabolism (among other pathways) were 
found to be elevated upon such treatment - a full table listing the significant growth condition-specific changes is 
provided in SI Table 2(a–c), all p-values were FDR corrected for 0.05). A similar analysis of the proteomics data 
revealed different results. While carnitine shuttle pathway activation was consistent with the gene expression 
Figure 1. Metabolic flux map of MCF7 breast cancer cells under MEM-Gln or MEM+Oli growth conditions 
compared to MEM condition. The fluxes were estimated by using Isodyn software. In each growth condition, 
the calculated flux was normalized against the flux of MEM growth condition in order to calculate the net 
change.
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analysis, the fatty acid pathways (activation, elongation and oxidation) were now found to be downregulated upon 
Oligomycin treatment. These results, consistent with previous observations both in yeast23,24 and in human25,26, 
point to the significant differences between the mRNA and protein levels of many metabolic enzymes and call for 
a systematic study of their potential functional regulatory implications.
Overview of the metabolic modeling based analysis. Our main goal in this study is to use the meas-
ured multi-omics data to systematically chart the different layers of metabolic regulation in breast cancer cells that 
orchestrate the actual metabolic flux across the network’s reactions occurring in each growth condition. Ideally, 
measuring the actual fluxes in each condition directly via tracing experiments would be adequate, but obviously, 
this can currently be done only for a small number of fluxes that are mainly involving central cell metabolism. 
Hence, alternatively, we integrated the various omics data measured in each growth condition within a genome 
scale model of human metabolism27 to infer the likely metabolic fluxes given these data in a genome wide man-
ner. After an initial validation of these predictions, we proceeded to compare the flux predictions of the resulting 
reactions to the corresponding enzymes’ omics data to identify their regulation. This is performed in a stepwise 
manner as follows (Fig. 2):
 1. GSMM based identification of transcriptional and translational directly regulated reactions: We first iden-
tify reactions that are directly regulated – that is, reactions whose model-based predicted flux alterations 
across the different conditions studied can be accounted for by molecular alterations at any one of the levels 
measured: those include reactions that are primarily transcriptionally regulated and primarily translation-
ally regulated. These assignments are done in a mutually exclusive manner, as follows: (1) transcriptionally 
regulated reactions (TR) are those reactions whose enzymes’ gene expression levels match the predicted 
fluxes. (2) translationally regulated reactions (TL) are those reactions whose predicted flux levels do not 
match their gene expression levels, but they match the protein levels of their enzymes.
 2. GSMM based identification of post-translationally directly regulated reactions: Post-translationally 
regulated reactions’ (PTL) assignments are given to the reactions where both the enzymes’ gene expres-
sion and proteomics levels do not match the predicted flux levels but the predicted flux levels across the 
different growth condition can be significantly associated with changes in the phosphorylation levels of the 
enzymes.
 3. Building machine learning predictors of additional directly regulated reactions: For the majority of the 
metabolic reactions, however, we did not find omics evidence testifying that they are directly regulated 
at any of these three levels. One major reason for that may be the limited scope of the proteomics and 
phospho-proteomics measurements. We, therefore, built machine learning based predictors of TR and TL 
regulation based on the reactions that have already been labeled as such via the model-based analysis in 
step (1). Then, we applied these predictors in a genome wide manner to further identify sets of reactions 
that are predicted to be TR or TL regulated (detailed below). We then performed various genome wide 
analyses to further test and validate the veracity of these predictions.
 4. Identifying stochiometrically coupled, indirectly regulated reactions: Finally, even after this prediction 
step, a large set of reactions still remains unassigned and are labeled as indirectly regulated. A major likely 
source of such indirect regulation is metabolic regulation28, which manifests itself in the stoichiometric cou-
pling of the fluxes of different reactions across the metabolic network, and which we study further using 
the human metabolic model.
Figure 2. Systematic identification of reactions’ regulation: Step 1: Using gene-expression and proteomics 
data to predict transcriptionally and translationally regulated reactions. Step 2: Using phospho-proteomic 
data to predict post-translationally regulated reactions. Step 3: Based on the results of step 1, build predictors 
of TR and TL regulation. Step 4: Identifying indirectly regulated reactions that are metabolically regulated via 
stoichiometric coupling.
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Below we provide a detailed description of each of these four steps and the results they uncover.
Step 1: Identifying transcriptionally regulated (TR) and translationally regulated (TL) reactions. 
We first aimed to predict the fluxes of the reactions in each condition, to determine which reactions are directly 
regulated and at what level they are regulated. To this end, we used iMAT (the integrative Metabolic Analysis 
Tool)17, a computational method that systematically predicts metabolic fluxes in a GSMM by incorporating omics 
data (transcriptomics and/or proteomics) that represent the activity level of the metabolic enzymes. iMAT con-
siders the gene expression or protein levels as cues for the likelihood that the enzymes in question carry a met-
abolic flux in their associated reactions. It then leverages the GSMM to accumulate these cues into a global flux 
distribution that is stochiometrically consistent and maintains mass balance across the entire metabolic network 
(see methods).
To this end we first tested if the above described procedure yields flux predictions that are in accordance 
with those quantified with 13C Metabolic Flux Analysis (13C MFA). To this end, we combined both mRNA and 
protein expression measurements and used iMAT, a tool that extends upon the standard flux balance analysis 
(FBA) to predict the flux distribution that is the most likely given both types of data. Briefly, following a proce-
dure already established and validated by17, the activity level of an enzyme was set according to the proteomics 
data when these data were available and according to the gene-expression otherwise, leaving the activity level 
unconstrained when large disparities existed between the gene expression and the proteomics data (see methods). 
Reassuringly, the accuracy of predicting the experimentally measured fluxes was significant across all growth 
conditions (Spearman correlation coefficient across all growth conditions = 0.42 p-values < 8.9671e-25, see Fig. 3 
for the correlations obtained at each of the three different growth conditions).
Given these network wide flux predictions, we next set to identify the reactions that are transcriptionally 
regulated (TR). To this end we discretized the gene expression measurements and the predicted fluxes into three 
levels of activity: low (TR-low), moderate (TR-moderate) and high (TR-high)). We then compared predicted 
flux level of each reaction to the discretized gene-expression level of the pertaining enzymes (see methods). 
Reactions whose predicted flux levels matched gene expression levels of their enzymes across the different meas-
urements were considered to be TR. For the three conditions (MEM-Gln, MEM and MEM+Oli), 562, 550 and 
556 reactions (approximately 28% of the model reactions) were identified as TR, respectively. Supporting these 
predictions, we found that the group of predicted TR reactions is enriched with transcription factor binding sites 
(using ENRICHR tool29,30, we calculated the enrichment according to several databases: Jaspar31 and Transfar32 
(hyper-geometric p-value = 9.5892e-05), ChEA33 (hyper-geometric p-value = 1.2819e-10) and ENCODE34,35 
(hyper-geometric p-value = 0.0029)) (see methods).
To predict translational regulation (TL), we searched for reactions whose (discretized) predicted flux activ-
ity levels were different from the transcriptomic levels of their enzymes. Such transcriptomic/flux ‘discordant’ 
reactions whose activity levels were high (low) according to the gene expression of their enzymes but low (high) 
according to the flux predictions are considered to be post-transcriptionally down-(up-)regulated. The corre-
lation between the proteomics data and the predicted fluxes for this subset of TL predicted reactions was high 
and significant (rho = 0.75, 0.6, 0.5, for the 3 growth conditions, all p-values < 0.0071), as would be expected (SI 
Fig. 1). It is important to note that in order to avoid circularity, this correlation was calculated in a cross-validation 
manner only for sub-group which was not constrained in the algorithm input. Among the reactions identified as 
post-transcriptionally regulated, we denoted the subset of reactions whose predicted flux state highly matches the 
proteomics (discretized) levels in a given growth condition as translationally (TL)-regulated. Among those, about 
15 reactions are predicted to be TL-upregulated (the discretized flux/proteomics activity state is higher than the 
discretized transcriptomics state), and about 35 are predicted to be TL-downregulated (the discretized flux/pro-
teomics activity state is lower than the discretized transcriptomics state) (SI Table 3). The specific pathways that 
are predicted to be TR (high/low/moderate) and TL (up/down) regulated are listed in SI Table 6(a–c).
Step 2: Identifying post-translational (PTL) regulated reactions. To identify the reactions that are 
post-translationally (PTL) regulated, we used the fluxes predicted in the previous step as a reference point. That is, 
reactions whose predicted flux activity markedly differed both from their transcriptomics and proteomics expres-
sion levels (that are hence not predicted to be TR or TL regulated) may be post-translationally (PTL)-regulated. 
Figure 3. Scatter plot depicting the association between the measured and predicted fluxes in each of the three 
media conditions. Flux predictions were obtained by integrating the transcriptomics and proteomics data 
within the human metabolic model, as described in the main text.
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Overall, 34, 39, 42 such reactions have at least one measured phosphorylation site in MEM, MEM-Gln and 
MEM+Oli, respectively. We next inferred the impact of each of the measured phosphorylation sites on enzyme 
activity. The phosphorylation data included 56 metabolic enzymes phosphorylated at 71 different phosphoryla-
tion sites catalyzing 164 metabolic reactions. For each of the reactions, we computed the Spearman rank correla-
tion between the predicted flux (computed via integrating the pertaining transcriptomics and proteomics data) 
and the corresponding site phosphorylation levels across all growth conditions and time points measured (SI 
Fig. 2). 19 reactions manifested a significant p-value (<0.05) with a strong correlation (Spearman rho > |0.6|). 
These 19 reactions have 13 different phosphorylation sites (SI, Fig. 3).
The functional impact of phosphorylation is currently known from the literature for only two of these 
enzymes: (1) phosphorylation of S1859 in carbamoyl-phosphate synthetase 2 (CAD) enhances its in vivo36 activ-
ity, and (2) phosphorylation on S293 causes pyruvate dehydrogenase (PDHA1) enzyme inactivation37. Our pre-
dictions match both; for the CAD enzyme, we detected a high positive correlation (0.718) and for PDHA1 we 
obtained a strong negative correlation of −0.6. To test and validate these predictions in our cells further, we per-
formed western blot experiments for both proteins (CAD and PDH together with their phosphorylated forms). 
We observed a marked phosphorylation of PDH in the predicted conditions for MEM-Gln and MEM+Oli com-
pared to MEM growth condition, indicating its reduced activity under these conditions (Fig. 4). This is addition-
ally confirmed via flux measurements through 13C MFA (SI, Table 1). On the other hand, we observed a decreased 
phosphorylation at CAD protein, indicating a decrease at its activity at MEM-Gln and MEM+Oli conditions, as 
predicted (Fig. 4).
Step 3: Genome wide prediction of TR and TL regulation of breast cancer metabolism. In the 
previous steps, we have identified about 500 reactions that are directly regulated at one of the three regulatory lev-
els described above (TR, TL or PTL). In these reactions, the predicted flux changes were significantly associated 
with molecular alterations in the pertaining enzymes. However, this leaves a large number of about 1450 reactions 
that were not assigned to any of these direct regulatory levels, which can be attributed to the limited scope of our 
measurements. In order to predict additional reactions that are likely to be directly regulated at TR or TL level, 
we built five Support Vector Machine (SVM) classifiers for five different direct regulation levels: TR-high, TR-low, 
TR-moderate, TL-up and TL-down. The goal of each classifier is to predict whether a reaction is regulated at one 
of these levels or not. The classifier was trained and evaluated using the reactions that have already been labeled 
as TR or TL regulated in the previous analysis at step (1), using a standard train and test 5-fold cross validation. 
The classifier input features included the gene expression, proteomics, predicted fluxes and metabolic network 
characteristics (reversibility information, number of participating metabolites, index of the relevant pathway, 
and more) of the given reactions, and the TR/TL labels already assigned in the previous steps (see methods). The 
accuracy of the classifier was measured by comparing the predicted labels against the known labels. The resulting 
classifiers achieved a high cross validation prediction accuracy (mean AUC > 0.946 for all classifiers, all values 
are presented in Fig. 5a; recall and precision values are presented in Fig. 5b). Applying this to predict the direct 
regulation of the 1450 remaining reactions, ~450 additional reactions were predicted to be regulated at exactly 
one of the TR/TL levels (in MEM, MEM-Gln and MEM+Oli, see Fig. 5c for their subdivision in each of the 
regulation groups). The predicted TR group is enriched with transcription factor binding sites (hyper-geometric 
p-value = 6.236e-119, see methods. Similarly, the predicted TL group has a significantly higher number of flux/
proteomic states matches compared to the randomly selected sets (empiric p-value = 0.04). It is important to note 
that the very small numbers of predicted PTL reactions did not enable us to build reliable predictors of regulation 
at this level. Interestingly, adding the new set of predicted reactions which are directly regulated to those reactions 
Figure 4. Phosphorylation of the indicated proteins (PDH and CAD) at MEM-Gln and MEM+Oli conditions 
were detected by western blot analysis.
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which are previously identified as directly regulated by model based integration uncovers a large number of new 
pathways that now become enriched in directly regulated reactions (SI Table 6).
Step 4: Studying the reactions that are indirectly regulated via stoichiometric coupling. After 
the predictions we performed at step 1–3, around 1000 reactions yet remained not to be predicted as directly 
regulated, some of which are likely to be further identified as regulated with more extensive data. However, many 
of these remaining unassigned reactions may still be truly indirectly regulated (IR) reactions where their flux 
may be primarily metabolically-regulated by changes in their substrate and product levels due to changes in 
the flux activities of other reactions in the metabolic network. That is, their flux may be stoichiometric coupling 
(SC-regulated) to the flux of other reactions in the metabolic network38–40.
In the framework of MCA (Metabolic Control Analysis), it has been established that network structure is 
an important determinant of metabolic control41. Accordingly, a perturbation in enzyme abundance or activity 
can be propagated through reactions stoichiometry coupled to the reaction catalyzed by such enzyme. To study 
such dependencies on a genome-scale, we used flux sampling to quantify the pairwise stoichiometric couplings 
between all the metabolic reactions in the human network, identifying for each reaction how tightly its flux is 
coupled to the flux of each of the other reactions, in each of the different conditions (see Methods).
Remarkably, we found that the ~1000 ‘unassigned’ indirect reactions have significantly higher stoichiometric 
couplings to the TL and PTL directly regulated reactions than among themselves across the different growth 
conditions (using one sided Wilcoxon test, p-values = 6.9163e-158 and 2.945e-14, respectively). These findings 
point out that the regulation of cellular metabolism may be governed in a hierarchical manner where the flux 
of many indirectly regulated reactions is determined via stoichiometric coupling to the flux of others, directly 
regulated reactions. Finally, we found that the group of ~1000 indirectly regulated reactions is highly enriched 
with bi-directional reactions (hyper-geometric p-value = 1.15e-28, 2.21e-32, 5.54e-32 for each condition, see 
Methods). This observation can be explained by metabolic control analysis (MCA)42 theory: In the framework 
of MCA, enzyme activities catalyzing reversible reactions, which often are in rapid equilibrium, usually have low 
flux control coefficients and hence are poor targets of direct regulation. Indeed, the combination of the ‘direc-
tional flexibility’ of candidate SC-regulated reactions with their enhanced coupling to other directly-regulated 
reactions is likely to facilitate the formation of stoichiometrically feasible flux distributions across the metabolic 
network, providing a way for efficiently regulating the metabolic state with minimal cellular costs in terms of 
transcriptomics, proteomics and phospho-proteomics regulation.
Discussion
This study integrates transcriptomics, proteomics, phospho-proteomics and fluxomics data with metabolic mod-
eling to provide the first chart of metabolic regulation in MCF7 breast cancer cells on genome scale. We classi-
fied the metabolic enzymes as those that are predicted to be directly regulated at three distinct levels (TR, TL, 
and PTL) and those that are predicted to be indirectly regulated, given the current coverage of omics data. As 
expected, we found that citric acid cycle is generally upregulated both on the transcription and translational level. 
Interestingly, while on the transcriptional level fatty acid oxidation was found to be generally down-regulated, it 
is up-regulated on the translational level. In addition, oxidative phosphorylation – another hallmark of cancer, 
was found to be up-regulated only on the translational level (not including MEM+Oli medium). These findings 
further highlight the pivotal role of translational regulation in cancer and the importance of obtaining higher 
coverage of proteomic data, whenever possible.
Figure 5. (a) AUC curves for each of the direct regulation SVM classifiers; (b) mean precision and recall 
values for each of the SVM classifiers; (c) number of reactions that have been uniquely predicted to be directly 
regulated by one of the classifiers.
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Remarkably, we found that the flux of the indirectly regulated reactions is coupled to the flux of directly regu-
lated ones. We also found that the indirectly regulated reactions are enriched with bi-directional reactions. These 
findings might open an opportunity for further research to determine an extent by which their activity levels are 
set by other reactions. Taken all together, these findings suggest that the regulation of breast cancer cell metab-
olism is controlled in a hierarchical manner where the direct regulation of about half of the reactions suffices to 
orchestrate the flux regulation through the whole metabolic network via flux coupling.
Like almost any other computational, genome scale investigation, our approach has quite a few limita-
tions. First, the data itself, is still limited and noisy, and the coverage of different layers of omics data is une-
ven, due to obvious technical limitations. Second, guided by the data we collected, we focused here on studying 
post-translational modifications mediated by phosphorylation. However, obviously, post-translational modifi-
cations occur via a variety of additional mechanisms, including, e.g., acetylation, glycosylation and allosteric 
regulation43,44. Consequently, the machine learning predictors built for predicting transcriptional regulation and 
post-transcriptional regulation, but not post-translational regulation. Fourthly, as we employ coarse discretiza-
tion to overcome some of the noise in the data, we only identify regulatory alterations in reactions that are differ-
entially active across the conditions of study. This limitation is partly mitigated, however, by analyzing three very 
distinct metabolic states. Future work should aim to address these limitations by incorporating data sets covering 
more conditions, measuring a wider range of omics data with higher coverage, and ideally, move to perform such 
measurements in patients’ tumor data. With the advent of omics technologies such data may become readily 
available soon and may be benefit from the conceptual and computational framework laid out in the current 
study.
Although we analyzed multiple layers of omics data, their coverage has been limited: while we had gene 
expression data for all 1372 metabolic genes, the coverage of our cutting-edge proteomics measurements pro-
vided data for only 486 metabolic enzymes and 71 of their phosphorylation sites. Flux measurements using 13C 
labeling are understandably even more limited in their scope, covering only central carbon metabolism. Aiming 
to make the best use of the available data and to obtain a genome-wide view of breast cancer cell metabolism, 
we used a modeling approach to integrate the data and infer the most likely genome-scale flux distributions. 
Additional work aiming to deal with the limited coverage problem was carried out via creating SVM predictors 
that used the known network properties together with measurements with high coverage and helped us extend 
the scope of the study to the utmost. With rapid advancement of high-throughput technology and accumula-
tion of more comprehensive omics data across additional cellular conditions, the conceptual and computational 
framework exhibited here lays the methodological foundations for gradually obtaining a more comprehensive 
view of metabolic regulation in both breast cancer and other cancer types.
Materials and Methods
Cell culture. Breast cancer cell line, MCF7 was purchased from ATCC and cultured in MEM without phenol 
red (Gibco, Thermo Fisher Scientific Inc., Waltham, MA, USA) containing 10% Fetal Bovine Serum (Sigma), 
10 mM d-glucose (Sigma-Aldrich), 1 mM sodium pyruvate (Biological Industries), 2 mM glutamine (Gibco), 
0.1% antibiotic (penicillin 10 Units/ml-streptomycin 10 Units/ml, Gibco), 0.01 mg/ml insulin (Sigma), and 1% 
non-essential amino acids (Biological Industries). The cells were maintained at 37 °C with 5% CO2 and saturated 
humidity. Growth medium was replaced every 2–3 days.
Many breast cancer cells, including MCF7, display glutamine addiction habits; that is, they rely on glutamine 
as the main source of energy rather than glucose45. Besides that, they also have elevated mitochondrial activity, 
and considering that hypoxia is a common condition in the tumor microenvironment, the study of metabolism 
in the presence of strong stress condition such as hypoxia is also particularly interesting. Therefore; to study the 
regulation of breast cancer cells, we applied these two perturbations; glutamine deprivation and mitochondrial 
inhibition by oligomycin.
For the experiments, MCF7 cells were seeded and 48 h later, the medium was exchanged with an adapta-
tion medium, MEM without phenol red (Gibco) containing 10% dialyzed Fetal Bovine Serum (Sigma) and 
the above-mentioned supplements. For the metabolomics experiments, after 24 h of incubation with adapta-
tion medium, for the MEM systems, the medium was exchanged with the same medium containing 10 mM 
[1,2-13C2]-glucose (Sigma) or 4 mM [U-13C5]-glutamine (Sigma) with or without oligomycin (1 µM). For the 
MEM-Gln systems the replaced growth medium did not contain glutamine but only 10 mM [1,2-13C2]-glucose 
(Sigma). The cells were counted at 0 h, 8 h and 24 h after tracer introduction, and cell pellet and media were imme-
diately frozen to use in later analysis. For the proteomic experiments heavy labeled MCF7 cells were used as an 
internal standard. To obtain complete labeling, cells were cultured in DMEM deprived of lysine and arginine, and 
supplemented with the heavy versions of these amino acids, 13C615N2-lysine (Lys8) and 13C615N4-arginine (Arg10). 
After ten cell doublings, complete labeling was achieved and validated by mass spectrometric analysis.
Biochemical assays. Glucose, lactate, glutamine and glutamate concentrations were determined by spec-
trophotometry (COBAS Mira Plus, Horiba ABX) from frozen cell culture medium as previously described46–48. 
Briefly, extracellular glucose was measured by calculating the NAD(P)H concentration decrease after the con-
version of total glucose by hexokinase and conversion of resulting glucose-6-phosphate into D-gluconate-
6-phosphate by G6PDH using coupled enzymatic reactions (ABX Pentra Glucose HK CP, HORIBA ABX, 
Montpellier, France). Lactate concentration was determined by lactate dehydrogenase (LDH) reaction and 
measurement of NADH change. Similarly, the glutamate concentration was determined by glutamate dehydroge-
nase (GDH) reaction and measurement of NADH change. To measure glutamine concentration, glutamine was 
first converted to glutamate by glutaminase (GLS) reaction and then glutamate concentration was quantified as 
described above. Consumption and production rates of metabolites in the cells were analyzed by measuring the 
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decrease or increase in concentration of the extracellular metabolites in the media at 8 h or 24 h compared to the 
initial concentration of the metabolite, with respect to the total cell number at each time point.
13C Assisted metabolomics. Isotopologue distribution analysis of intracellular and extracellular metab-
olites was performed by gas chromatography coupled to mass spectrometry (GC-MS). All GC-MS analysis was 
carried out using an Agilent 7890 A GC equipped with HP5 capillary column connected to an Agilent 5975 C MS. 
GC-MS analysis of fatty acids was carried out using a GCMS-QP 2012 Shimadzu coupled with bpx70 (SGE) col-
umn. For all measurements, 1 µL of sample was injected at 250 °C, helium as the carrier gas, at a flow rate of 1 mL 
per minute. Each metabolite or metabolite set had different isolation, derivatization and detection procedures 
as explained in49–51. Raw mass spectra of metabolites were corrected for natural abundance of 13C, 29Si, 30Si, 33S, 
34S to compute the fractions of 13C incorporated into the analyzed metabolic products from artificially labeled 
substrates. Data are available via Metabolights with identifier MTBLS183. (https://www.ebi.ac.uk/metabolights)
13C Metabolic flux analysis (13C MFA). Our in-house developed software, Isodyn [https://github.com/
seliv55/isodyn], was used to simulate the transfer of the tracers from [1,2-13C2]-glucose or [U-13C5]-glutamine 
medium into intracellular metabolites. Isodyn is a program written in C++ and designed to simulate the dynam-
ics of metabolite labeling by stable isotopic tracers18–22. This program automatically constructs and solves a large 
system of ordinary differential equations which describe the evolution of isotopologue concentrations of metab-
olites produced in glycolysis, TCA cycle and PPP. Initially, all the metabolites except for introduced labeled sub-
strates with known isotopologue composition in the medium are considered to be non-labeled and initial total 
concentrations of intracellular metabolites are calculated as a function of model parameters assuming a steady 
state at the initial moment. There is a function designed specifically for each type of reaction (i.e. carboxylation, 
decarboxylation) and these functions simulate transformation of carbon skeleton (specific transition of labeled 
carbon) and consumption and production rates of each isotopologue in the considered system. These transfor-
mations redistribute 13C isotopes in all metabolites, so that, individual rates which determine the values of the 
derivatives for the isotopologues are calculated for each isotopologue. To solve this system, a method of numerical 
integration is chosen arbitrarily (Runge-Kutta, BDF, Dassl). Isodyn simulates a real-time course of label propa-
gation starting from the initial values of experimental conditions of incubation. As it compares the experimental 
and computed data for corresponding time points, reaching an isotopic steady state is not necessary.
Western blot. Cell extracts were obtained from fresh plates 24 h after incubation with the corresponding 
growth medium. Then, cells were incubated for 30 min on ice with lysis buffer, scraped, sonicated and centrifuged 
at 15,000 g for 20 minutes at 4 °C. Supernatants were recovered and the protein content was quantified by the BCA 
kit (Pierce Biotechnology). Western blot analysis was carried out size-separating an equal amount of protein by 
electrophoresis on SDS polyacrylamide gels, and then the proteins were electroblotted onto polyvinylidene fluo-
ride transfer membranes (PVDF) (Bio-Rad Laboratories, Hercules, CA, USA). The membranes were blocked with 
5% of non-fat dry milk in PBS with 0.1% Tween, and then incubated with specific primary antibodies overnight 
at 4 °C. Next, membranes were treated with the appropriate secondary antibody for 1 hour at room temperature. 
All blots were visualized on Fujifilm X-ray (VWR International, Radnor, PA, USA) with chemiluminescence 
detection using Immobilon ECL Western Blotting Detection Kit Reagent (EMD Millipore, Billerica, MA, USA). 
The antibodies used were CAD (Santacruz Biotechnology), CAD-P (Cell Signaling), PDH (Merck Millipore) 
PDH-P (Cell signaling) and β-actin (MP Biomedicals). Also, anti-mouse (Dako) and, Anti-rabbit (Amersham 
Biosciences) secondary antibodies were used.
Transcriptomics analysis. mRNA was extracted from cells using GeneAll Hybrid miRNA kit according to 
manufacturer instructions. mRNA was then processed on Atlas machine using Affymetrix Human Gene 2.1 ST 
Array Strip and WT expression kit. CEL files were analyzed using Affymetrix Expression Console software. The 
data were converted to log2 RMA values.
Proteomics and phosphoproteomics analysis. MCF7 cells were lysed in buffer containing 4% SDS, 
100 mM DTT in Tris-HCl pH 7.5. Equal protein amounts were combined with the SILAC standard and 5–10 mg 
proteins were digested using the FASP protocol52. From each sample, 10 ug were taken for proteomic analysis, and 
the rest was used for phospho-peptide enrichment with IMAC. Single runs were performed for each proteomic 
and phospho-proteomic sample.
MS analysis was performed on the EASY-nLC1000 nano-HPLC coupled to the Q-Exactive MS (Thermo 
Scientific). Peptides were separated on PepMap C18 columns using 200 min gradients. Raw MS files were ana-
lyzed with MaxQuant. Database search was performed with the Andromeda search engine using the Uniprot 
database. A decoy database was used to determine a 1% FDR cutoff on the peptide and protein levels. For 
phospho-proteomic analysis, the database search included p(STY) sites as variable modifications. Data are avail-
able via ProteomeXchange with identifier PXD006449 (http://www.proteomexchange.org/)
Genome-scale metabolic modeling (GSMM). A metabolic network consisting of m metabolites and 
n reactions can be represented by a stoichiometric matrix S, where the entry Sij represents the stoichiometric 
coefficient of metabolite i in reaction j53. A GSMM model imposes mass balance, directionality, and flux capacity 
constraints on the space of possible fluxes in the metabolic network’s reactions through a set of linear equations:
S v 0⋅ =
≤ ≤v v vmin max
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where v stands for the flux vector for all of the reactions in the model (i.e. the flux distribution). The exchange of 
metabolites with the environment is represented as a set of exchange (transport) reactions, enabling a pre-defined 
set of metabolites to be either taken up or secreted from the growth media. The steady-state assumption rep-
resented in equation (1) constrains the production rate of each metabolite to be equal to its consumption rate. 
Enzymatic directionality and flux capacity constraints define lower and upper bounds on the fluxes and are 
embedded in equation (2).
In the following, flux vectors satisfying these conditions will be referred to as feasible steady-state flux 
distributions.
Pathway enrichment analysis. Based on iMAT results, which was used to predict the regulation of the 
reactions in the metabolic model, a hypergeometric p-value was computed for each pathway in the model for 
being enriched with reactions that are regulated in each level. Data for reactions and their pathways were taken 
from BIGG database54. A correction for multiple hypotheses was done using false discovery rate method of 0.05.
Using iMAT with transcriptomics and proteomics as its input. We first employed a discrete rep-
resentation of significantly high or low enzyme-expression levels across tissues. Gene expression and proteomics 
levels were discretized to highly (1), lowly (-1), or moderately (0) expressed, for each sample. This discretization 
was conducted as follows: the 1/3 of the proteomics with the highest values to be considered as highly expressed, 
and vice versa for lowly expressed. When proteomics data was not available, transcriptomics data was used (again 
– top 1/3 as lowly expressed, and vice versa). One could argue that the different levels of coverage between tran-
scriptomics and proteomics could suggest using different thresholds for determining ‘active’ and ‘inactive’ genes 
in the respective analysis; To keep a systematic approach, here we opted to treat both data measurements in the 
same, uniform, way (but other approaches may be taken in the future. Lastly, in order to avoid direct effect of the 
coverage differences between proteomics and transcriptomics, we determined a moderate expression level for 
genes whose level according to the gene expression was high (low) and according to the proteomics low (high), 
and left their corresponding enzymes/reactions unconstrained. In iMAT analysis, the discretized gene expression 
levels were incorporated into the metabolic model to predict a set of high and low activity reactions. Network 
integration was done by mapping the genes to the reactions according to the metabolic model (see methods), 
and by solving a constraint-based modeling (CBM) optimization problem to find a steady-state metabolic flux 
distribution. CBM models the cell as a network of metabolic reactions controlled by hundreds of genes and ena-
bles the prediction of feasible metabolic behavior under different genetic and environmental conditions, that are 
expressed as constraints in the network55,56. By using the CBM approach, we assign permissible flux ranges to all 
the reactions in the network, in a way that satisfies the stoichiometric and thermodynamic constraints embedded 
in the model and maximizes the number of reactions whose activity is consistent with their expression state. 
iMAT’s solution may not be unique as a space of alternative optimal solutions (in terms of its objective func-
tion) may exist. Therefore, we sampled 2,000 different flux distributions that are all consistent with the reactions’ 
state of activity or inactivity defined in one of iMAT’s optimal solutions. To address the potential degeneracy of 
the CBM solutions, we used the artificial-center-hit-and-run (ACHR) sampling approach57 which is an efficient 
sampling approach for a linearly constrained space58 (mean, min and max flux and flux range for each reaction is 
provided in SI). The mean flux distribution obtained over the 2,000 samples then serves as an approximation of 
the source metabolic state.
Gene to reaction mapping. To map the gene expression to expression on the reaction level, we used the 
boolean gene-protein-reaction (GPR) associations available in the H. sapiens recon1 metabolic model, down-
loaded from the BIGG database (52). These rules indicate which genes need to be expressed using the two 
Boolean operators “and” and “or”. An example of such a rule is the following:
R1 = (g1 or g2) and g3 (indicating that either gene 1 or gene 2 (or both) need to be expressed in combination 
with gene 3 to allow reaction 1 activity.
OR rules were converted to the maximum transcription level of either of the genes, i.e. (g1 or g2) was con-
verted to max(g1, g2)
AND rules were converted to the minimum transcription level of either of the genes, i.e. (g1 and g2) was 
converted to min(g1, g2).
Bi-directional reactions. Bi-directional reactions are those that can potentially carry flux in both directions 
(this information is provided in the human GSMM model).
Identifying TR/TL reactions. We compared the discretized gene expression measurements to the activity 
levels of the predicted fluxes; we took 1/3 of the reactions with the highest flux values to be considered as highly 
active, and vice versa for lowly active reactions. The rest of the reactions considered to be moderately active. If 
the activity level of a reaction matches the discretized value according to the gene expression, in at least 3 out of 
the 4 cell line replicates, the reaction is considered to be TR. For the rest of the reactions, if the activity level of a 
reaction matches the discretized value according to the proteomics, the reaction is considered to be TL.
Identifying PTL reaction. Among the reactions that haven’t been classified as TR or TL in the way that 
mentioned above, we found the sub group of reactions that were associated with at least one phosphorylation site. 
Reactions whose predicted flux activity markedly differed from their transcriptomics or proteomics expression 
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levels, and that were associated with at least one phosphorylation site in 3 of the 4 cell line replications, were pre-
dicted to be potentially post-translationally (PTL) regulated.
Finding transcription factor enrichment. First, we found the reactions that were predicted to be TR in 
all condition. Then, using the reaction-gene matrix, we found the list of genes that catalyze this group of reactions. 
Using ENRICHR tool29,30, we found how many of the genes have (at least one) TFs that bind to their promoter 
region, from exploring Jaspar31, Transfar32, ChEA33 and ENCODE34,35 databases. Same for all model genes. These 
values were used in the hypergeometric calculation.
Support vector machine (SVM) classification. We built and trained five SVMs classifiers (representing 
5 “classes” of regulation, as described in main text). We applied an SVM classifier with a quadratic kernel for each 
classifier, with the following features:
(1–4) gene expression measurements under 4 data points
(5–8) predicted fluxes under 4 data points
(9) A binary integer indicating if the reaction is reversible.
(10) An integer value associated with a unique metabolic pathway.
(11) The total number of metabolites participating in the reaction.
(12) The total number of substrates participating in the reaction.
(13) The total number of products participating in the reaction.
For the labels, we used the classification of the reactions from the previous steps (1 if it’s regulated at that level, 
0 otherwise). All SVM classifiers were trained on part of this data, and later tested on all data (mean recall and 
precision values presented in the text).
Cross-validation was performed by setting aside one fifth of the regulated-predicted reactions in the training 
set. The classifier was trained on the remaining four. The classifier’s accuracy was measured by comparing the 
predicted labels against the known labels.
Computing pairwise flux correlations. For each growth condition, we found 2000 different flux distribu-
tions using flux balance analysis. Then, for each pair of reactions, we calculated the Spearman correlation between 
their flux values. For the coupling calculations, we used the absolute values of these correlations (as coupling 
between reactions can be either positive or negative).
Multiple hypotheses correction. Throughout our paper P-values were filtered by False Discovery Rate 
(FDR) to correct for multiple testing59. More specifically, first, all the p-values were sorted in increasing order, P1, 
P2,.., Pn. Next, we filtered p-values pi: pi > i
n
 * 0.05.
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